MWNA
SANA icon

Marshall Wace North America’s Sana Biotechnology SANA Stock Holding History

Marshall Wace North America’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-38,570
Closed -$1.29M – 1729
2021
Q1 		$1.29M Buy
+38,570
New +$1.26M 0.01% 954

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace North America's SANA Position: Q2 2021 in Review

Marshall Wace North America sold out of Sana Biotechnology (SANA) in Q2 2021, closing a stake of 38,570 shares — an estimated $1.29M sold.

Marshall Wace North America first reported a position in SANA in Q1 2021 and held it in 1 quarter. The position peaked at $1.29M in Q1 2021. 80 funds tracked by Wall St. Rank hold SANA as of Q2 2021.

  • Marshall Wace North America reported no remaining Sana Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 38,570 Sana Biotechnology shares in Q2 2021, an estimated $1.29M.
  • Marshall Wace North America first reported a position in Sana Biotechnology in Q1 2021 and held it in 1 quarter.
  • Marshall Wace North America's Sana Biotechnology position peaked at $1.29M in Q1 2021.
  • 80 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.